Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 901 | Bone Marrow | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 5 |
| 902 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 903 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 34 |
| 904 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 61 |
| 905 | Apheresis | Allogeneic | Myelodysplastic Syndrome/Myeloproliferative neoplasm | Hematology | 2025 | Standard Therapy | NETHERLANDS | 62 |
| 906 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Austria | 68 |
| 907 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 908 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 909 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 77 |
| 910 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 12 |
| 911 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 912 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 67 |
| 913 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 4 |
| 914 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 73 |
| 915 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 916 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Italy | 50 |
| 917 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 39 |
| 918 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 43 |
| 919 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 66 |
| 920 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2025 | Standard Therapy | USA | 61 |
| 921 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Austria | 55 |
| 922 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 69 |
| 923 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Denmark | 67 |
| 924 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | United Kingdom | 75 |
| 925 | Apheresis | Allogeneic | T – cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 24 |
| 926 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Belgium | 68 |
| 927 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 42 |
| 928 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 50 |
| 929 | Apheresis | Allogeneic | Prolymphocytic Leukemia | Hematology | 2025 | Standard Therapy | USA | 62 |
| 930 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | United Kingdom | 62 |
| 931 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 932 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 85 |
| 933 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 54 |
| 934 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | USA | 39 |
| 935 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 45 |
| 936 | Apheresis | Autologous | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 59 |
| 937 | Apheresis | Allogeneic | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 938 | Apheresis | Allogeneic | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 939 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 73 |
| 940 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 941 | Apheresis | Autologous | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 69 |
| 942 | Apheresis | Autologous | Hodgkin lymphoma | Hematology | 2025 | Standard Therapy | Germany | 38 |
| 943 | Apheresis | Allogeneic | Tcell acute leukemia | Hematology | 2025 | Standard Therapy | Romania | 31 |
| 944 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Italy | 37 |
| 945 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 69 |
| 946 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 55 |
| 947 | Apheresis | Allogeneic | Fanconi’s Anemia | Hematology | 2025 | Standard Therapy | Russia | 14 |
| 948 | Apheresis | Allogeneic | Peripheral T-cell Lymphoma not otherwise specified | Hematology | 2025 | Standard Therapy | Germany | 54 |
| 949 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 63 |
| 950 | Apheresis | Allogeneic | Myeloid Sarcoma | Hematology | 2025 | Standard Therapy | Poland | 48 |
| 951 | Apheresis | Allogeneic | Other Myelofibrosis/Myelosclerosis | Hematology | 2025 | Standard Therapy | USA | 72 |
| 952 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Germany | 11 |
| 953 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 37 |
| 954 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2025 | Standard Therapy | Australia | 59 |
| 955 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 35 |
| 956 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 957 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 59 |
| 958 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 70 |
| 959 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 70 |
| 960 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 66 |
| 961 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 962 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 963 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Italy | 61 |
| 964 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 71 |
| 965 | Apheresis | Allogeneic | Chronic Lymphocytic Leukemia | Hematology | 2025 | Standard Therapy | Czechia | 45 |
| 966 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Brazil | 61 |
| 967 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Hungary | 35 |
| 968 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | NETHERLANDS | 48 |
| 969 | Apheresis | Allogeneic | Mantle Cell Lymphoma | Hematology | 2025 | Standard Therapy | Ireland | 62 |
| 970 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 62 |
| 971 | Apheresis | Allogeneic | Acute Myeloid Leukemia, Myelodysplasia-Related | Hematology | 2025 | Standard Therapy | Russia | 53 |
| 972 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 56 |
| 973 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 68 |
| 974 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 975 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 976 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 977 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 52 |
| 978 | Apheresis | Autologous | Diffuse large B-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 63 |
| 979 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 980 | Apheresis | Autologous | Central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 981 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 74 |
| 982 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 983 | Apheresis | Allogeneic | T-cell prolymphocytic leukemia | Hematology | 2025 | Standard Therapy | Germany | 53 |
| 984 | Apheresis | Autologous | Central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 985 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 986 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 54 |
| 987 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 41 |
| 988 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 32 |
| 989 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 72 |
| 990 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Poland | 52 |
| 991 | Apheresis | Allogeneic | Chronic Myeloid Leukemia | Hematology | 2025 | Standard Therapy | Poland | 50 |
| 992 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 17 |
| 993 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 66 |
| 994 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2025 | Standard Therapy | Poland | 49 |
| 995 | Apheresis | Allogeneic | Chronic Granulomatous Disease | Hematology | 2025 | Standard Therapy | Poland | 5 |
| 996 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 55 |
| 997 | Apheresis | Allogeneic | Diffuse Large B-cell Lymphoma | Hematology | 2025 | Standard Therapy | Poland | 68 |
| 998 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 64 |
| 999 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 51 |
| 1000 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 58 |